Background & Aims: Pancreatitis remains the major complication of endoscopic retrograde
cholangiopancreatography (ERCP), and hyperenzymemia after ERCP is common. Because …

Objectives: Previous studies have shown that ulinastatin may be effective at preventing
pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). However …

Background It has been reported that the administration of ulinastatin, gabexate mesylate, or
somatostatin may be effective in the prevention of post-endoscopic retrograde …

Objectives: The role of prophylactic ulinastatin in the prevention of post-endoscopic
retrograde cholangiopancreatography (ERCP) pancreatitis is debated. A meta-analysis of all …

Abstract Background and Aim: Endoscopic retrograde cholangiopancreatography (ERCP) is
a useful diagnostic and therapeutic procedure; however, ERCP occasionally causes post …

Abstract Background and Objectives Ulinastatin, an intrinsic trypsin inhibitor, has proved to
be effective for the prevention of acute pancreatitis after endoscopic retrograde …

Pancreatitis remains the most common and potentially fatal complication following ERCP.
Various pharmacological agents have been used in an attempt to prevent post-ERCP …

Background: ulinastatin is reported to inhibit pro-inflammatory markers and also inhibits
coagulation and fibrinolysis. the drug is available in East asia for the treatment of acute …

BACKGROUND AND OBJECTIVES:: The prophylactic use of protease inhibitors in patients
undergoing ERCP is still controversial. Our purpose was to evaluate the efficacy of protease …

Objectives: Pancreatitis is the most common major complication of endoscopic retrograde
cholangiopancreatography (ERCP). Efforts have been made to identify pharmacologic …